Pemvidutide
Also known as: ALT-801, GLP-1/glucagon dual agonist
Pemvidutide is a catalog-expanded glp1 entry in ProtoComp's source-backed compound corpus. It is included for search, calculator math, stack awareness, and future research curation based on expand compound catalog, explicit_target_list, local_seed, project_target. Published dosing, cycle length, and clinical-use claims are intentionally left null until compound-specific evidence is reviewed.
Phase 2 MOMENTUM (obesity) and IMPACT (MASH) trials used 1.2, 1.8, and 2.4 mg weekly. Phase 3 not yet initiated as of 2026.
No published cycle data available.
Contraindications
- • Personal or family history of medullary thyroid carcinoma (class label)
Common side effects
- • Nausea
- • Vomiting
- • Diarrhea
- • Decreased appetite
Serious risks
- • Pancreatitis risk (class effect)
- • Modest LDL increase observed in trials
Drug interactions
- • Insulin
- • Sulfonylureas
Requires monitoring
- • Blood glucose
- • Lipid panel
- • Heart rate
Pregnancy / breastfeeding
Avoid — limited human data
- Designed for both obesity and MASH (NASH) — same molecule pursued in two indications
- LDL increase is mechanism-related and may attenuate over time, but warrants lipid monitoring
Sign in to calculate your dose, add this compound to your stack, and check for interactions with your current cabinet.